Vascular brachytherapy firm Novoste has reported fiscal 2002 revenue of $69 million, down slightly compared with $69.9 million for fiscal 2001. For the year (end-December 31), the Norcross, GA-based vendor had a net loss of $13 million, compared with a net loss of $5.1 million in 2001.
For the fourth quarter, Novoste reported revenue of $14.6 million, compared with $22.4 million reported for the fourth quarter of 2001. Net loss for the fourth quarter was $4.6 million compared with net income of $2.7 million in the same period last year.
By AuntMinnie.com staff writersFebruary 6, 2003
Related Reading
Novak tapped as Novoste president and CEO, October 17, 2002
In-stent restenosis brachytherapy benefits from longer radiation sources, March 18, 2002
Radiation proves robust for preventing in-stent restenosis, September 10, 2001
Gamma radiation reduces in-stent restenosis rate in saphenous vein grafts, March 20, 2001
FDA likely to approve new brachytherapy for coronary artery restenosis, September 26, 2000
Copyright © 2003 AuntMinnie.com
